Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
by Zacks Equity Research
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $62.32 in the latest trading session, marking a +1.02% move from the prior day.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $62.63, moving +0.47% from the previous trading session.
The Zacks Analyst Blog Highlights Union Pacific, AT&T, Blackstone, Gilead Sciences and Waste Management
by Zacks Equity Research
Union Pacific, AT&T, Blackstone, Gilead Sciences and Waste Management are included in this Analyst Blog.
Top Research Reports for Union Pacific, AT&T & Blackstone
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Union Pacific Corporation (UNP), AT&T Inc. (T) and Blackstone Inc. (BX).
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for LVHD
Gilead Sciences (GILD) Stock Moves -1.67%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $63.50 in the latest trading session, marking a -1.67% move from the prior day.
Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose
by Zacks Equity Research
Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir
Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion
by Zacks Equity Research
Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
Gilead Sciences (GILD) Stock Moves -0.28%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $65, marking a -0.28% move from the previous day.
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
by Zacks Equity Research
Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.
Company News for Sep 13, 2022
by Zacks Equity Research
Companies in The News Are: AAPL, BMY, TWTR, GILD
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Should First Trust Large Cap Core AlphaDEX ETF (FEX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FEX
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $65.28, marking a +0.28% move from the previous day.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $65.10, moving +0.48% from the previous trading session.
Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.
Halozyme Therapeutics (HALO) Down 10.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FEX
Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication
by Zacks Equity Research
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.